Related Experiment Video
Updated: May 4, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
2.8K
An update on mechanical circulatory support for heart failure therapy
Hadi Daood Toeg1, Talal Al-Atassi, Jose Perez Garcia
1aDivision of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada bDivision of Cardiac Surgery, Harvard University, Massachusetts General Hospital, Boston, Massachusetts, USA.
Current Opinion in Cardiology
|January 8, 2014
Summary
Mechanical circulatory support (MCS) offers a promising treatment for advanced heart failure. Newer continuous flow left ventricular assist devices (LVADs) show improved durability and survival, making them a viable option for destination therapy.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Refractory heart failure necessitates advanced treatment options.
- Mechanical circulatory support (MCS) has evolved significantly over time.
Purpose of the Study:
- To review current studies on MCS for heart failure.
- To explore future mechanical treatment alternatives.
Main Methods:
- Review of contemporary studies utilizing MCS.
- Analysis of advancements in mechanical assist devices.
Main Results:
- Early MCS devices had high adverse event rates.
- Modern continuous flow left ventricular assist devices (LVADs) demonstrate improved durability and reduced morbidity.
- Increased use of LVADs for destination therapy is observed.
Conclusions:
- Second and third-generation continuous flow LVADs offer enhanced durability and survival.
- MCS is becoming a primary treatment for refractory heart failure.
- Future developments aim for less invasive, smaller, and more efficient MCS devices.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K